GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000609112 | Liver | Cirrhotic | generation of precursor metabolites and energy | 238/4634 | 490/18723 | 6.85e-31 | 1.07e-27 | 238 |
GO:001598012 | Liver | Cirrhotic | energy derivation by oxidation of organic compounds | 154/4634 | 318/18723 | 3.11e-20 | 8.87e-18 | 154 |
GO:009719312 | Liver | Cirrhotic | intrinsic apoptotic signaling pathway | 130/4634 | 288/18723 | 2.69e-14 | 2.45e-12 | 130 |
GO:000599612 | Liver | Cirrhotic | monosaccharide metabolic process | 104/4634 | 257/18723 | 1.74e-08 | 6.32e-07 | 104 |
GO:001931812 | Liver | Cirrhotic | hexose metabolic process | 97/4634 | 237/18723 | 2.67e-08 | 9.16e-07 | 97 |
GO:000600611 | Liver | Cirrhotic | glucose metabolic process | 82/4634 | 196/18723 | 1.01e-07 | 2.93e-06 | 82 |
GO:006201212 | Liver | Cirrhotic | regulation of small molecule metabolic process | 124/4634 | 334/18723 | 2.74e-07 | 6.79e-06 | 124 |
GO:004346712 | Liver | Cirrhotic | regulation of generation of precursor metabolites and energy | 58/4634 | 130/18723 | 5.81e-07 | 1.28e-05 | 58 |
GO:007233112 | Liver | Cirrhotic | signal transduction by p53 class mediator | 69/4634 | 163/18723 | 5.97e-07 | 1.30e-05 | 69 |
GO:00723326 | Liver | Cirrhotic | intrinsic apoptotic signaling pathway by p53 class mediator | 38/4634 | 76/18723 | 1.75e-06 | 3.32e-05 | 38 |
GO:000610911 | Liver | Cirrhotic | regulation of carbohydrate metabolic process | 70/4634 | 178/18723 | 1.14e-05 | 1.62e-04 | 70 |
GO:00086306 | Liver | Cirrhotic | intrinsic apoptotic signaling pathway in response to DNA damage | 42/4634 | 99/18723 | 8.44e-05 | 9.17e-04 | 42 |
GO:00427716 | Liver | Cirrhotic | intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator | 22/4634 | 43/18723 | 1.69e-04 | 1.59e-03 | 22 |
GO:004426211 | Liver | Cirrhotic | cellular carbohydrate metabolic process | 97/4634 | 283/18723 | 1.89e-04 | 1.76e-03 | 97 |
GO:00160511 | Liver | Cirrhotic | carbohydrate biosynthetic process | 73/4634 | 202/18723 | 1.91e-04 | 1.77e-03 | 73 |
GO:00109061 | Liver | Cirrhotic | regulation of glucose metabolic process | 47/4634 | 119/18723 | 2.61e-04 | 2.33e-03 | 47 |
GO:00106751 | Liver | Cirrhotic | regulation of cellular carbohydrate metabolic process | 54/4634 | 146/18723 | 6.53e-04 | 4.96e-03 | 54 |
GO:190179612 | Liver | Cirrhotic | regulation of signal transduction by p53 class mediator | 37/4634 | 93/18723 | 9.58e-04 | 6.78e-03 | 37 |
GO:00059771 | Liver | Cirrhotic | glycogen metabolic process | 30/4634 | 72/18723 | 1.18e-03 | 7.98e-03 | 30 |
GO:00060731 | Liver | Cirrhotic | cellular glucan metabolic process | 30/4634 | 73/18723 | 1.53e-03 | 9.99e-03 | 30 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DYRK2 | SNV | Missense_Mutation | | c.1133G>T | p.Arg378Leu | p.R378L | Q92630 | protein_coding | deleterious(0) | probably_damaging(0.933) | TCGA-A2-A0SV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate therapy | zometa | PD |
DYRK2 | SNV | Missense_Mutation | rs773264334 | c.1592N>A | p.Arg531Gln | p.R531Q | Q92630 | protein_coding | tolerated(0.15) | probably_damaging(0.964) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DYRK2 | SNV | Missense_Mutation | | c.1520T>C | p.Leu507Pro | p.L507P | Q92630 | protein_coding | deleterious(0.02) | possibly_damaging(0.899) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DYRK2 | SNV | Missense_Mutation | rs756215589 | c.70N>T | p.Val24Phe | p.V24F | Q92630 | protein_coding | tolerated_low_confidence(0.21) | benign(0.011) | TCGA-BH-A203-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DYRK2 | SNV | Missense_Mutation | | c.271N>G | p.Gln91Glu | p.Q91E | Q92630 | protein_coding | tolerated_low_confidence(0.61) | benign(0.003) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
DYRK2 | insertion | In_Frame_Ins | novel | c.1766_1767insAGATATAGAAGATGGTCGTTTCTTGTCAGTCTCGTTAGTTTTAGT | p.Asn589delinsLysAspIleGluAspGlyArgPheLeuSerValSerLeuValLeuVal | p.N589delinsKDIEDGRFLSVSLVLV | Q92630 | protein_coding | | | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DYRK2 | SNV | Missense_Mutation | novel | c.610N>C | p.Asp204His | p.D204H | Q92630 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
DYRK2 | SNV | Missense_Mutation | rs748801595 | c.1447N>T | p.Arg483Trp | p.R483W | Q92630 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
DYRK2 | SNV | Missense_Mutation | novel | c.1210N>C | p.Asp404His | p.D404H | Q92630 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
DYRK2 | SNV | Missense_Mutation | | c.563N>T | p.Ala188Val | p.A188V | Q92630 | protein_coding | deleterious(0.01) | probably_damaging(0.942) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | PMID28766366-Compound-Scheme21Left | | |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 249565847 | | |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 249565807 | | |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | PMID28766366-Compound-Scheme16DMAT | | |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | HARMINE | HARMINE | 22998443 |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | LEUCETTAMINE B | LEUCETTAMINE B | 22998443 |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | HARMINE | HARMINE | |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | PMID28766366-Compound-Scheme14BINDY | | |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 249565851 | | |
8445 | DYRK2 | SERINE THREONINE KINASE, TYROSINE KINASE, KINASE, DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | PMID28766366-Compound-Scheme21Right | | |